CVS Health quarterly financial reports

CVS Health Switch to Hyrimoz Biosimilar Captures 36% Market Share

Apr 16, 2024, 02:25 PM

Following a strategic shift by CVS Health, the prescription of biosimilar versions of Humira, notably Hyrimoz, has seen a significant surge. CVS Health, through its PBM Caremark which covers approximately 30 million US patients, removed Humira from its formulary on April 1st and replaced it with Hyrimoz, marketed by CVS's subsidiary Cordavis. This change led to an increase in Hyrimoz prescriptions from 640 to 8300 in just one week, capturing a market share of 36% from just 5%. The market share for Hyrimoz notably increased, while other Humira biosimilars did not experience similar growth. Approximately half of the new prescriptions for Humira biosimilars were for Hyrimoz, despite there being nine different biosimilars available in the U.S. market.